Advertisement
Screener

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

ARROWHEAD PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Revenue

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Increase (Decrease) in Deferred Revenue of -$5.27 million for the 12-month period ending 2018-09-30, per its 10-K filed 2018-12-11.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-12-11

  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was -$942.60K.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$621.80K.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$310.00K.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$3.39M, a 113.23% decline year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2018 was -$5.27M, a 3435.30% decline from fiscal 2017.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2017 was $157.98K, a 96.84% decline from fiscal 2016.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2016 was $5.00M.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2018-09-30-$942.60K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-11
-$1.56M
derived: sum of 2 quarters · filed 2018-12-11
-$1.87M
derived: sum of 3 quarters · filed 2018-12-11
-$5.27M
10-K · filed 2018-12-11
2018-06-30-$621.80K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-07
-$931.80K
derived: sum of 2 quarters · filed 2018-08-07
-$4.33M
10-Q · filed 2018-08-07
-$12.96M
derived: sum of 4 quarters · filed 2018-12-11
2018-03-31-$310.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-08
-$3.70M
10-Q · filed 2018-05-08
-$12.34M
derived: sum of 3 quarters · filed 2018-12-11
-$20.85M
derived: sum of 4 quarters · filed 2018-12-11
2017-12-31-$3.39M
10-Q · filed 2018-02-09
-$12.03M
derived: sum of 2 quarters · filed 2018-12-11
-$20.54M
derived: sum of 3 quarters · filed 2018-12-11
-$28.89M
derived: sum of 4 quarters · filed 2018-12-11
2017-09-30-$8.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-11
-$17.15M
derived: sum of 2 quarters · filed 2018-12-11
-$25.49M
derived: sum of 3 quarters · filed 2018-12-11
$157.98K
10-K · filed 2018-12-11
2017-06-30-$8.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-07
-$16.86M
derived: sum of 2 quarters · filed 2018-08-07
$8.80M
10-Q · filed 2018-08-07
2017-03-31-$8.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-08
$17.31M
10-Q · filed 2018-05-08
2016-12-31$25.65M
10-Q · filed 2018-02-09
2016-09-30$5.00M
10-K · filed 2018-12-11
2016-03-31-$37.50K
10-Q · filed 2017-05-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74